ArticleInternational urology and nephrology2025
Lipoprotein(a) levels and cardiovascular mortality risk in Chinese patients undergoing hemodialysis.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLipoprotein(a) (Lp(a)) is recognized as an independent risk factor for cardiovascular disease (CVD) in the general population. However, its impact on CVD mortality among Chinese patients undergoing maintenance hemodialysis (MHD) has not been fully established. This study aimed to evaluate the association between Lp(a) levels and both CVD mortality and all-cause mortality in this population.
methodsA retrospective cohort study was conducted involving 200 MHD patients from Beijing Tongren Hospital, analyzed from January 1, 2013, to July 1, 2024. The mortality outcomes included CVD-related and all-cause mortality. Kaplan-Meier survival curves were utilized to assess the impact of Lp(a), while Cox regression analysis and restrict cubic spline were performed to explore associations.
resultsThe median follow-up duration was 66.5 months, with 121 deaths recorded (60.5%), of which 66 (54.5%) were due to CVD. Kaplan-Meier analysis indicated that patients in the highest tertile of Lp(a) levels had the lowest survival for both CVD mortality and all-cause mortality. In multivariable Cox regression, higher Lp(a) levels were independently associated with an increased risk of both CVD mortality and all-cause mortality. The restricted cubic splines regression model showed that the risk of CVD mortality and all-cause mortality increased with rising Lp(a) levels.
conclusionElevated serum Lp(a) levels are independently associated with increased mortality from both CVD and all causes in Chinese MHD patients. These findings indicate that serum Lp(a) may be a significant risk factor for CVD mortality in this population.
Indexed as
Identifiers
40128433What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.